ISA101 and nivolumab for HPV-16+ cancer: updated clinical efficacy and immune correlates of response | Journal for ImmunoTherapy of Cancer

Log In More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Browse by collection

Archive

Authors

About
Log in More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Article metrics

PDF +
Supplementary
Material

Clinical/translational cancer immunotherapy

ISA101 and nivolumab for HPV-16⁺ cancer: updated clinical efficacy and immune correlates of response

Online download statistics by month:

Online download statistics by month: February 2022 to October 2023

	Abstract	Full	Pdf
Feb 2022	460	468	141
Mar 2022	788	801	271
Apr 2022	332	342	119
May 2022	241	243	82
Jun 2022	204	209	75
Jul 2022	198	204	57
Aug 2022	200	204	56
Sep 2022	186	192	67
Oct 2022	262	271	72
Nov 2022	201	201	72
Dec 2022	188	189	72
Jan 2023	146	146	61
Feb 2023	169	170	65
Mar 2023	168	170	74
Apr 2023	129	129	62
May 2023	170	172	72
Jun 2023	114	117	37
Jul 2023	132	133	56
Aug 2023	92	92	69
Sep 2023	173	174	66
Oct 2023	242	246	51
Total	4795	4873	1697